259 related articles for article (PubMed ID: 7646580)
1. [In vitro activity of sparfloxacin against methicillin-resistant staphylococci].
Wallrauch C; Voss A; Milatovic D; Braveny I
Arzneimittelforschung; 1995 Jun; 45(6):723-5. PubMed ID: 7646580
[TBL] [Abstract][Full Text] [Related]
2. In vitro activity of sparfloxacin and three other fluoroquinolones against methicillin-resistant Staphylococcus aureus and Staphylococcus epidermidis.
Smith KR; Cobbs CG
Eur J Clin Microbiol Infect Dis; 1992 Jan; 11(1):55-8. PubMed ID: 1314175
[TBL] [Abstract][Full Text] [Related]
3. Quinolone resistance in Staphylococci: activities of new nonfluorinated quinolones against molecular targets in whole cells and clinical isolates.
Roychoudhury S; Catrenich CE; McIntosh EJ; McKeever HD; Makin KM; Koenigs PM; Ledoussal B
Antimicrob Agents Chemother; 2001 Apr; 45(4):1115-20. PubMed ID: 11257024
[TBL] [Abstract][Full Text] [Related]
4. Effect of different combinations of sparfloxacin, oxacillin, and fosfomycin against methicillin-resistant staphylococci.
Ferrara A; Dos Santos C; Cimbro M; Gialdroni Grassi G
Eur J Clin Microbiol Infect Dis; 1997 Jul; 16(7):535-7. PubMed ID: 9272391
[TBL] [Abstract][Full Text] [Related]
5. Comparative in vitro activity of sparfloxacin (AT 4140, RP 64206--SPFX) against 275 multiresistant clinical isolates.
Giamarellou H; Voutsinas D; Xirouchaki E
J Chemother; 1992 Feb; 4(1):12-5. PubMed ID: 1328554
[TBL] [Abstract][Full Text] [Related]
6. In vitro activity of levofloxacin against coagulase-positive and -negative staphylococci.
Cafiso V; Messina C; Santagati M; Campanile F; Bonfiglio G; Stefani S
Drugs Exp Clin Res; 2001; 27(3):107-11. PubMed ID: 11447768
[TBL] [Abstract][Full Text] [Related]
7. The in-vitro activity of Bay y 3118, a new chlorofluoroquinolone.
Wise R; Andrews JM; Brenwald N
J Antimicrob Chemother; 1993 Jan; 31(1):73-80. PubMed ID: 8383104
[TBL] [Abstract][Full Text] [Related]
8. In-vitro activity of four new fluoroquinolones.
García-Rodríguez JA; García Sánchez JE; García García MI; Fresnadillo MJ; Trujillano I; García Sánchez E
J Antimicrob Chemother; 1994 Jul; 34(1):53-64. PubMed ID: 7961215
[TBL] [Abstract][Full Text] [Related]
9. In vitro evaluation of sparfloxacin activity and spectrum against 24,940 pathogens isolated in the United States and Canada, the final analysis.
Jones RN; Ballow CH; Schentag JJ; Johnson DM; Deinhart JA
Diagn Microbiol Infect Dis; 1998 May; 31(1):313-25. PubMed ID: 9597392
[TBL] [Abstract][Full Text] [Related]
10. [Comparative activity of daptomycin against clinical isolates of methicillin-resistant Staphylococcus aureus and coagulase-negative staphylococci].
Picazo JJ; Betriu C; Rodríguez-Avial I; Culebras E; López F; Gómez M;
Enferm Infecc Microbiol Clin; 2010 Jan; 28(1):13-6. PubMed ID: 19406529
[TBL] [Abstract][Full Text] [Related]
11. In vitro activity of sparfloxacin, ciprofloxacin, ofloxacin, and other antibiotics against bloodstream isolates of gram-positive cocci.
Rotstein C; Amsterdam D; Beam TR; Mandell LA; Gorzynski EA
Diagn Microbiol Infect Dis; 1993 Jul; 17(1):85-91. PubMed ID: 8395375
[TBL] [Abstract][Full Text] [Related]
12. In vitro activity of sparfloxacin and six reference antibiotics against gram-positive bacteria.
Louie A; Baltch AL; Ritz WJ; Smith RP
Chemotherapy; 1991; 37(4):275-82. PubMed ID: 1665123
[TBL] [Abstract][Full Text] [Related]
13. Activity of new quinolones against ciprofloxacin-resistant staphylococci.
Forstall GJ; Knapp CC; Washington JA
Antimicrob Agents Chemother; 1991 Aug; 35(8):1679-81. PubMed ID: 1656873
[TBL] [Abstract][Full Text] [Related]
14. Comparison of sparfloxacin, temafloxacin, and ciprofloxacin for prophylaxis and treatment of experimental foreign-body infection by methicillin-resistant Staphylococcus aureus.
Cagni A; Chuard C; Vaudaux PE; Schrenzel J; Lew DP
Antimicrob Agents Chemother; 1995 Aug; 39(8):1655-60. PubMed ID: 7486895
[TBL] [Abstract][Full Text] [Related]
15. Comparative activity of garenoxacin and other agents by susceptibility and time-kill testing against Staphylococcus aureus, Streptococcus pyogenes and respiratory pathogens.
Noviello S; Ianniello F; Leone S; Esposito S
J Antimicrob Chemother; 2003 Nov; 52(5):869-72. PubMed ID: 14519672
[TBL] [Abstract][Full Text] [Related]
16. grlA and gyrA mutations and antimicrobial susceptibility in clinical isolates of ciprofloxacin- methicillin-resistant Staphylococcus aureus.
Coskun-Ari FF; Bosgelmez-Tinaz G
Eur J Med Res; 2008 Aug; 13(8):366-70. PubMed ID: 18952518
[TBL] [Abstract][Full Text] [Related]
17. In vitro antimicrobial activity of fluoroquinolones against clinical isolates obtained in 1989 and 1990.
Chen YC; Chang SC; Hsu LY; Hsieh WC; Luh KT
J Formos Med Assoc; 1993 Dec; 92(12):1040-8. PubMed ID: 7911351
[TBL] [Abstract][Full Text] [Related]
18. Activity of nadifloxacin against methicillin-resistant Staphylococcus aureus isolated from skin infections: comparative study with seven other fluoroquinolones.
Nishijima S; Nakagawa M; Tsuboi N; Akamatsu H; Horio T; Fujita M; Kawabata S
J Int Med Res; 1996; 24(1):12-6. PubMed ID: 8674789
[TBL] [Abstract][Full Text] [Related]
19. [The rate of inducible clindamycin resistance and susceptibilities to other antimicrobial agents in staphylococci].
Oğuz VA; Yapar N; Sezak N; Cavuş SA; Kurutepe S; Peksel H; Cakir N; Yüce A
Mikrobiyol Bul; 2009 Jan; 43(1):37-44. PubMed ID: 19334378
[TBL] [Abstract][Full Text] [Related]
20. In-vitro activity of three fluoroquinolones, cefotaxime and clindamycin against staphylococci.
Schumacher-Perdreau F; Peters G
Zentralbl Bakteriol; 1995 Oct; 282(4):389-93. PubMed ID: 9810661
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
